|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM013632590 |
| 003 |
DE-627 |
| 005 |
20250124134922.0 |
| 007 |
tu |
| 008 |
231221s1992 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed25n0046.xml
|
| 035 |
|
|
|a (DE-627)NLM013632590
|
| 035 |
|
|
|a (NLM)1381869
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Park, Y C
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A multicenter, fixed-flexible dose study of terazosin hydrochloride in the treatment of symptomatic benign prostatic hypertrophy
|
| 264 |
|
1 |
|c 1992
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 13.10.1992
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a In this study the multicenter, fixed-flexible dose regimen was taken to evaluate the effective dose range of Terazosin for the treatment of micturition disturbance in benign prostatic hypertrophy (BPH) and to clarify the characteristics of patients who are more responsive to Terazosin therapy. After a 1-week washout (placebo) the first two weeks 1 mg/day of Terazosin was administered, then depending on efficacy of subjective symptoms, Terazosin doses were increased up to 2 mg/day and 4 mg/day at intervals of two weeks. After six weeks the final efficacy and safety were assessed. The subjective symptom improvement rate was 18.5% by 1 mg/day, 55.6% by 2 mg/day and 65.4% by 4 mg/day cumulatively. The objective symptom improvement rate were 13.2% by 1 mg/day, 42.1% by 2 mg/day and 50.0% by 4 mg/day cumulatively. The global improvement rate was 14.5% by 1 mg/day, 50.0% by 2 mg/day and 61.8% by 4 mg/day cumulatively. The patients who had a higher subjective symptom score in the lead-in period were more improved rather than those who had a lower score. In objective symptoms, voided volume, maximum flow rate (MFR), MFR nomogram score and average flow rate improved and the ratio of residual urine volume decreased. There was no relationship between clinical improvement on either subjective or objective symptoms and prostatic weight. Adverse reactions, such as dizziness, vertigo, tinnitus, nausea and blurred vision; were seen in 10 cases. In conclusion Terazosin was effective and well tolerated for the treatment of patients who had micturition disturbance with BPH in the dose range of 2 to 4 mg/day
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Multicenter Study
|
| 650 |
|
7 |
|a Adrenergic alpha-Antagonists
|2 NLM
|
| 650 |
|
7 |
|a Terazosin
|2 NLM
|
| 650 |
|
7 |
|a 8L5014XET7
|2 NLM
|
| 650 |
|
7 |
|a Prazosin
|2 NLM
|
| 650 |
|
7 |
|a XM03YJ541D
|2 NLM
|
| 700 |
1 |
|
|a Nishioka, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Arai, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tomoyoshi, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kurita, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hayashida, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nagai, N
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Inoue, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kataoka, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kitagawa, Y
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 38(1992), 7 vom: 01. Juli, Seite 857-68
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnas
|
| 773 |
1 |
8 |
|g volume:38
|g year:1992
|g number:7
|g day:01
|g month:07
|g pages:857-68
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 38
|j 1992
|e 7
|b 01
|c 07
|h 857-68
|